Expanding the Psoriasis Framework: Immunopathogenesis and Treatment Updates.

Area of Science:

• Dermatology and Immunology
• Molecular Biology

Background:

• Psoriasis is a chronic inflammatory skin disease with complex immune system involvement.
• The Interleukin-23 (IL-23)/Interleukin-17 (IL-17) signaling pathway is central to psoriasis pathogenesis.
• Other cytokines like IL-17C, IL-17F, IL-36, and Tyrosine Kinase 2 (TYK2) also play significant roles.

Purpose of the Study:

• To review recent discoveries in the immunopathogenesis of psoriasis.
• To summarize novel therapeutic targets and emerging treatments for psoriasis.
• To highlight advancements in understanding the molecular mechanisms driving psoriasis.

Main Methods:

• Literature review of recent scientific publications.
• Analysis of key signaling pathways involved in psoriasis.
• Summary of clinical findings for new antipsoriasis therapies.

Main Results:

• IL-23/IL-17 signaling is critical for epidermal hyperplasia and psoriatic plaque formation.
• Synergistic interactions between IL-17, IL-23, and other cytokines (IL-12, IL-22, IL-36, TNF, IFN) create a self-sustaining inflammatory circuit.
• Novel therapies targeting IL-36, IL-17F, aryl hydrocarbon receptors (AHRs), phosphodiesterase 4 (PDE4), and TYK2 show promise.

Conclusions:

• Recent research has significantly advanced the understanding of psoriasis immunopathogenesis.
• Emerging therapies targeting specific cytokines and signaling pathways offer new hope for patients.
• Continued research is essential for further improving psoriasis management strategies.